Late-Onset Neutropenia after Rituximab-Containing Therapy for Non-Hodgkin Lymphoma

Clinical Lymphoma, Myeloma and Leukemia

Volumn 15, Issue 12, 2015, Pages 761-765

  Aguiar Bujanda, David ^a   Blanco Sánchez, María Jesús ^a   Hernández Sosa, María ^a   Galván Ruíz, Saray ^a   Hernández Sarmiento, Samuel ^a   Saura Grau, Salvador ^a   Bohn Sarmiento, Uriel ^a  

^a HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

Author keywords

Anti CD20; Anticancer therapy; Chemoimmunotherapy; Haematological toxicity; Secondary effects

Indexed keywords

ANTIBIOTIC AGENT; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; RITUXIMAB; ANTINEOPLASTIC AGENT;

ADULT; AGED; ANEMIA; ARTICLE; BONE MARROW BIOPSY; BRONCHITIS; CAUSE OF DEATH; DISEASE COURSE; DISEASE DURATION; FATALITY; FEMALE; HUMAN; HUMAN TISSUE; HYPOPLASIA; IMMUNOGLOBULIN BLOOD LEVEL; INFECTIOUS COMPLICATION; LATE ONSET NEUTROPENIA; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; NEUTROPENIA; NEUTROPHIL COUNT; NONHODGKIN LYMPHOMA; PNEUMONIA; RETREATMENT; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; TREATMENT DURATION; VERY ELDERLY; CHEMICALLY INDUCED; LYMPHOMA, NON-HODGKIN; MIDDLE AGED;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEUTROPENIA; RETROSPECTIVE STUDIES; RITUXIMAB;

EID: 84952628304     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2015.07.635     Document Type: Article

References (22)

1. B. Coiffier Rituximab therapy in malignant lymphoma Oncogene 26 2007 3603 3613
2. N.E. Abdulla, M.J. Ninan, and A.B. Markowitz Rituximab: current status as therapy for malignant and benign hematologic disorders BioDrugs 26 2012 71 82
3. R. Ram, I. Ben-Bassat, O. Shpilberg, and et al. The late adverse events of rituximab therapy - rare but there! Leuk Lymphoma 50 2009 1083 1095
4. M. Benyunes, P. Multani, and A. Saunders Neutropenia in patients treated with rituximab [response letter] N Engl J Med 348 2003 2691 2694
5. K. Chaiwatanatorn, N. Lee, A. Grigg, and et al. Delayed-onset neutropenia associated with rituximab therapy Br J Haematol 121 2003 913 918
6. K. Dunleavy, F. Hakim, H.K. Kim, and et al. B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis Blood 106 2005 795 802
7. K. Fukuno, H. Tsurumi, N. Ando, and et al. Late-onset neutropenia in patients treated with rituximab for non-Hodgkin's lymphoma Int J Hematol 84 2006 242 247
8. C. Cattaneo, P. Spedini, S. Casari, and et al. Delayed-onset peripheral blood cytopenia after rituximab: frequency and risk factor assessment in a consecutive series of 77 treatments Leuk Lymphoma 47 2006 1013 1017
9. E. Nitta, K. Izutsu, T. Sato, and et al. A high incidence of late-onset neutropenia following rituximab-containing chemotherapy as a primary treatment of CD20- positive B-cell lymphoma: a single-institution study Ann Oncol 18 2007 364 369
10. D. Tesfa, T. Gelius, B. Sander, and et al. Late-onset neutropenia associated with rituximab therapy: evidence for a maturation arrest at the (pro)myelocyte stage of granulopoiesis Med Oncol 25 2008 374 379
11. G.G. Lai, S.T. Lim, M. Tao, and et al. Late-onset neutropenia following RCHOP chemotherapy in diffuse large B-cell lymphoma Am J Hematol 84 2009 414 417
12. S. Rozman, M. Sonc, and B.J. Novakovic Late-onset neutropenia following primary treatment of diffuse large B-cell lymphoma with rituximab-containing therapy Leuk Lymphoma 53 2012 1945 1948
13. J.H. Liu, S. Wei, T. Lamy, and et al. Chronic neutropenia mediated by fas ligand Blood 95 2000 3219 3222
14. B. Lemieux, S. Tartas, C. Traulle, and et al. Rituximab-related late-onset neutropenia after autologous stem cell transplantation for aggressive non-Hodgkin's lymphoma Bone Marrow Transplant 33 2004 921 923
15. Y. Hirayama, K. Kohda, Y. Konuma, and et al. Late onset neutropenia and immunoglobulin suppression of the patients with malignant lymphoma following autologous stem cell transplantation with rituximab Intern Med 48 2009 57 60
16. R. Cairoli, G. Grillo, A. Tedeschi, and et al. High incidence of neutropenia in patients treated with rituximab after autologous stem cell transplantation Haematologica 89 2004 361 363
17. S.C. Li, Y.C. Chen, A.M. Evens, and et al. Rituximab-induced late-onset neutropenia in newly diagnosed B-cell lymphoma correlates with Fc receptor FcγRIIIa 158(V/F) polymorphism Am J Hematol 85 2010 810 812
18. W.K. Weng, R.S. Negrin, P. Lavori, and et al. Immunoglobulin G Fc receptor FcgammaRIIIa 158 V/F polymorphism correlates with rituximab-induced neutropenia after autologous transplantation in patients with non-Hodgkin's lymphoma J Clin Oncol 28 2010 279 284
19. C. Keane, J.P. Nourse, P. Crooks, and et al. Homozygous FCGR3A-158V alleles predispose to late onset neutropenia after CHOP-R for diffuse large B-cell lymphoma Intern Med J 42 2012 1113 1119
20. D. Tesfa, S. Ajeganova, H. Hagglund, and et al. Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections Arthritis Rheum 63 2011 2209 2214
21. H. Kato, K. Yamamoto, K. Matsuo, and et al. Clinical impact and predisposing factors of delayed-onset neutropenia after autologous hematopoietic stem cell transplantation for B-cell non-Hodgkin lymphoma: association with an incremental risk of infectious events Ann Oncol 21 2010 1699 1705
22. I. Hincks, B.E. Woodcock, and J. Thachil Is rituximab-induced late-onset neutropenia a good prognostic indicator in lymphoproliferatve disorders? Br J Haematol 153 2011 411 413